FIG. 1



7.5
7.0
6.5
6.0
5.5
Log copy nbr of 111S DNA/g of feces
IBS
IBS+BH
IBS
IBS+BH
IBS
IBS+BH
D0
D14
D28

FIG. 2



45
40
35
30
25
20
15
10
5
0
Contraction nbrs/5 min
0
0.4
0.8
1.2
Distension volume (mL)
IBS
IBS+BH culture
IBS+BH Lyoph

FIG. 3



Impact of BH culture on microbiota
12
11
10
9
8
7
6
5
Log 10 bacteria/g of feces
Total bacteria
Enterobacteria
Bifidobacterium
SRB
Lactate utilizer SRB
IBS
IBS+BH

FIG. 4

Impact of BH lyophilisate on microbiota




FIG. 5



Impact of BH on caecal microbiota fermentation concentration
– short chain fatty acids
Caecal SCFA contration mM
100
80
60
40
20
0
Acetic acid
Propionic acid
Butyric acid
IBS
IBS+BH

FIG. 6

Impact of BH lyophilisate on microbiota fermentation – caecal sulphides




FIG. 7



Nbr of abdominal contractions / 5 min
0
10
20
30
40
50
0
0,4
0,8
1,2
Distension volume (mL)
LEEM
LEEM+BH
p< 0,05
p< 0,05

FIG. 8



p< 0,05
IBS
IBS+BH
Nber of abdominal contractions / 5 min
0
5
10
15
20
25
30
35
0
0,4
0,8
1,2
Distension volume (mL)

FIG. 9A



180
160
140
120
100
80
60
p< 0,05
IBS
IBS+BH

FIG. 9B



140
120
100
80
60
40
20
0
H2S mg/L
p< 0,05
IBS
IBS+BH

FIG. 10A




FIG. 10B





FIG. 11



B. hydrogenotrophica administrated (log_{10} per ml)

FIG. 12



Log10 nb copies /g feces
9.0
8.5
8.0
7.5
7.0
6.5
6.0
5.5
5.0
Administration period
Wash out period
Time(h)
0
24
48
72
96
120
144
168
192
216
240
264
288
(days)
0
1
2
3
4
5
6
7
8
9
10
11
12
Control
B. hydrogenotrohica

FIG. 13



Caecum
Feces
8,0
7,5
7,0
6,5
6,0
Log10 nb copies / g
Healthy HIM rat control
Healthy HIM Rat MIH treated

FIG. 14



120
100
80
60
40
20
0
mMol
*
*
Control Rats
Treated Rats
Acetate
Propionate
Butyrate
Lactate

FIG. 15



Control IBS HIM rats
IBS HIM rats treated with B.H. (14 days)
Log N/g selles
14
12
10
8
6
4
*
**
Total Anaerobes
Sulphate reducers
B. h

FIG. 16



B.h. administration
H2S (mg/l)
180
160
140
120
100
80
60
40
20
0
**
Control IBS HIM rats
Treated IBS HIM rats

FIG. 17



90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
% of Patients
Blautix
Placebo
Improvement
No Change
Worsening

FIG. 18



45%
40%
35%
30%
25%
20%
15%
10%
5%
0%
% of Patients
Blautix
Placebo
Improvement
No Change
Worsening

FIG. 19



9
8
7
6
p = 0,030
p = 0,036
Log10 Nb copy of 16S rDNA gene / g faeces
D0
D 28
IBS HMA-rats (n=17)
IBS HMA-rats + BlautiX (n=21)

FIG. 20



IBS HMA-rats (n=15)
IBS HMA-rats + BlautiX (n=17)
Healthy HMA-rats (n=19)
35
30
25
20
15
10
5
0
Abdominal contractions (number//5 min)
p = 0,025
0
0.4
0.8
1.2
Volume of distension (mL)

FIG. 21



12
11
10
9
8
7
6
Log10 nb of bacteria / g faeces
p = 0,023
total anaerobic bacteria
Enterobacteriaceae
Bifidobacteria
H2 utlising SRB
Lactate utilising SRB
IBS HMA-rats
IBS HMA-rats + BlautiX

FIG. 22



100
90
80
70
60
Caecal concentration mg/L
p = 0,04
sulphides
IBS HMA-rat (n=17)
IBS HMA-rat + BlautiX (n=21)

FIG. 23A




FIG. 23B

